NEW YORK, NY / ACCESSWIRE / November 24, 2015 / Market Exclusive announces that Maxim Group has reiterated a Buy rating for DelMar Pharmaceuticals, Inc. (DMPI) with a 12-month price target of $8.00 per share. The analyst note was published following the Company's third quarter business update call and presentation of updated data from the Phase II study of VAL-083 in refractory Glioblastoma Multiforme (GBM).
DelMar's recently presented interim Phase II data showed that the anti-tumor activity of VAL-083, unaffected by MGMT, can potentially overcome the development of drug resistance associated with temozolomide therapy. In reviewing DelMar's lead drug candidate, VAL-083, Maxim analyst Jason Kolbert writes, "VAL-083 could be the new standard of care in GBM."
About Market Exclusive
Market Exclusive Is a financial portal geared to engaging discussion on current financial topics. Market Exclusive is not an investment advisor.
The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
SOURCE: Market Exclusive